ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best American Penny Stocks to Buy According to Analysts. On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK’s Medicines and Healthcare products Regulatory Agency has approved ANKTIVA with Bacillus Calmette-Guérin for treating certain bladder cancer patients.
This is significant as it marks the first approval for the company outside of the United States of America. Moreover, the drug is a first-in-class IL-15 agonist, which works by activating and multiplying immune cells, specifically NK cells and T cells that help the body fight cancer.
A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.
In addition, clinical studies have shown strong results as some patients maintained a complete response for over 47 months at the last review.
ImmunityBio, Inc. is a biopharmaceutical company that develops therapies and vaccines that boost the immune system to fight cancer and infectious diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
